ESTRO 2024 - Abstract Book

S1188

Clinical - Head & neck

ESTRO 2024

Results:

50 patients treated for HPC were identified. 19 patients remained disease-free and free from other potentially confounding medical issues at 6 months post-treatment and were eligible for inclusion. 14 patients consented to the data collection and are included in the analysis. Demographic, disease and treatment details along with feeding tube data is shown in table 1. MDADI and PSS-HN subscales were categorised for ease of interpretation according to established cut-off points in previous clinical trials and are shown in figures 1&2. Feeding tube requirement before/during treatment was 42.9% (reasons: 4 patients with evidence of aspiration, 2 patients requiring nutrition support). Feeding tube in situ at >6 months had reduced to 21.4%. In all cases this was due to aspiration. The composite MDADI and PSS-HN Normalcy of Diet scales showed the majority of patients in this cohort reported adequate or optimal swallow-related QOL post-treatment, with modest to no impairment of maximal oral diet textures.

PSS-HN Eating in Public scales were more varied, with 43% of patients reporting moderate to severe impairment in function.

n

%

Total

14

Age (Median (range))

68.5 (51-86)

Male

12

84.6

PS0 PS1 PS2 PS3

7 3 3 1 2 4 3 3 2

50 21.4 21.4 7.1 14.3 28.6 21.4 21.4 14.3

T1 T2 T3

T4a T4b

Radiotherapy

6

42.9

Chemoradiotherapy

8

57.1

Feeding tube required before/during treatment 6

42.9

Feeding tube in situ at follow up

3

21.4